Predictors of Early Death in Patients With Wild‐Type Transthyretin Cardiac Amyloidosis
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.036755 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Paolo Milani und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine University of Pavia Italy. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background For the time being, tafamidis is the only approved treatment for wild‐type transthyretin cardiac amyloidosis. However, benefits on all‐cause death only emerge after ≈18 months. The current available staging systems are unable to specifically discriminate patients at high risk of death within 18 months from diagnosis, and the selection of patients who are expected to benefit from tafamidis is left to the clinical judgment of treating physicians, being often based primarily (and sometimes only) on age. We searched baseline variables able to discriminate patients at risk of death within 18 months. Methods and Results We randomly divided our prospectively maintained database in 2 cohorts, a testing (two thirds) and a validating (one third) set, respectively. We used the Eastern Cooperative Oncology Group–Performance Status as a simple scoring of frailty. We analyzed the clinical, laboratory and instrumental features of 691 consecutive wild‐type transthyretin cardiac amyloidosis patients diagnosed between 2006 and 2021. Median follow‐up was 43 months, and 367 patients (53%) died. Eighteen‐month death was predicted by NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide; cutoff 4200 ng/L), cardiac troponin I (cutoff 92 ng/L), and age (cutoff 80 years). At multivariable analysis, Eastern Cooperative Oncology Group–Performance Status >1 along with the selected variables were independent prognostic determinants and outperformed New York Heart Association functional class. The combination of these variables identified standard‐ and high‐risk patients (all variables above the cutoffs) with a median survival of 57 and 17 months, respectively ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine University of Pavia Italy.
- Amyloidosis Research and Treatment Center Foundation IRCCS Policlinico San Matteo Pavia Italy.
- Clinical and Interventional Cardiology Sassari University Hospital Sassari Italy.
- Cardiology Universitary Department IRCCS Policlinico San Donato San Donato Milanese Italy.
- Institute of Cardiology, Maggiore Hospital Crema Italy.
- Cardiocentro Bellinzona Italy.
ORCID-Profile: Paolo Milani, Giuseppe Damiano Sanna, Roberta Mussinelli, Gianluigi Guida, Andrea Attanasio, Laura Obici, Mario Nuvolone, Gavino Casu, Stefano Perlini, Giampaolo Merlini, Giovanni Palladini
Zitieren
APA
Milani, P., Sanna, G. D., Mussinelli, R., Basset, M., Guida, G., Attanasio, A., Nanci, M., Fabris, F., Bellofiore, C., Fogliani, A., Novello, E., Benigna, F., Obici, L., Benvenuti, P., Ciardo, M., Nuvolone, M., Averaimo, M., Casu, G., Foli, A., …, & Palladini, G. (2025). Predictors of Early Death in Patients With Wild‐Type Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.036755
Vancouver
Milani P, Sanna GD, Mussinelli R, Basset M, Guida G, Attanasio A, et al. Predictors of Early Death in Patients With Wild‐Type Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.036755
BibTeX
@article{Milani2025,
author = {Milani, Paolo and Sanna, Giuseppe Damiano and Mussinelli, Roberta and Basset, Marco and Guida, Gianluigi and Attanasio, Andrea and Nanci, Martina and Fabris, Francesca and Bellofiore, Claudia and Fogliani, Alessandro and Novello, Elisa and Benigna, Francesca and Obici, Laura and Benvenuti, Pietro and Ciardo, Martina and Nuvolone, Mario and Averaimo, Manuela and Casu, Gavino and Foli, Andrea and Perlini, Stefano and Merlini, Giampaolo and Palladini, Giovanni},
title = {Predictors of Early Death in Patients With Wild‐Type Transthyretin Cardiac Amyloidosis},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.036755}
}
EUVIMED